PHARMAC responds on salbutamol [1]

New Zealand Medical Journal

Volumn 118, Issue 1221, 2005, Pages

  Metcalfe, Scott ^a   Moodie, Peter ^b   Davies, Andrew ^b   McNee, Wayne ^b   Dougherty, Sean ^b  

^a PHARMAC ^*

^b Pharmaceutical Society   (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

AEROMIR; ALCOHOL; CHLOROFLUOROCARBON; CORTICOSTEROID; FLUTICASONE PROPIONATE; GENERIC DRUG; SALBUTAMOL; SALMETEROL XINAFOATE; SOLVENT;

ASTHMA; BIOEQUIVALENCE; CLINICAL TRIAL; DRUG APPROVAL; DRUG COST; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG FORMULATION; DRUG PACKAGING; DRUG SAFETY; EDUCATION PROGRAM; HUMAN; HYGIENE; LETTER; METERED DOSE INHALER; PALATABILITY; PATIENT ATTITUDE;

EID: 27244434596     PISSN: 11758716     EISSN: 11758716     Source Type: Journal    
DOI: None     Document Type: Letter

References (16)

1. Williamson IJ, Reid A, Monie RD, et al. Generic inhaled salbutamol. A randomised double-blind study. Postgrad Med. 1997;73:156-8.
2. Pinto Pereira LM, Clement YN, Pinto Pereira SM. Comparison of innovator and generic salbutamol inhalers: a double-blind randomised study of efficacy and tolerance. In J Clin Pharmacol Res. 2002;22:73-80.
3. Data Sheets for Salamol™ CFC-Free Inhaler, Ventolin® Inhaler (CFC-Free) and Airomir® Inhaler. Available online. URL: http://www.medsafe.govt.nz/profs.htm Accessed August 2005.
4. Gilchrist E et al. Remind patients to wash their MDI devices (letter). Pharm J. 2003;270:792.
5. Medicines and Healthcare products Regulatory Agency, Committee on Safety of Medicines Reminder: Blockage of CFC-free inhalers. Current Problems in Pharmacovigilance. 2001;27:3. Available online. URL: http://medicines.mhra.gov.uk/ourwork/monitorsafequalmed/currentproblems/ cpfeb2001.pdf Accessed August 2005.
6. Ke D, Kader AA. Tolerance of 'Valencia' Oranges to Controlled Atmospheres, as Determined by Physiological Responses and Quality Attributes. J Amer Soc Hort Sci. 1990;115:779.
7. Harrison LI, Donnell D, Simmons JL, et al. Twenty-eight-day double-blind safety study of an HFA-134g Inhalation Aerosol System in Healthy Subjects. J Pharm Pharmacol. 1996;48:596-600.
8. Barry PW, O'Callaghan C. Metered dose inhaler increases breath alcohol levels. Resp Med. 1999, 93:167-8.
9. New Zealand Public Health and Disability Act 2000, Section 49 Pharmac to consult in implementing objectives and carrying out functions.
10. Operating policies and procedures of the Pharmaceutical Management Agency ("PHARMAC"), 2nd edition. Wellington: PHARMAC; January 2001. Available online. URL: http://www.pharmac.govt.nz/pdf/opps.pdf (Section 4.2 Consultation) Accessed August 2005.
11. Operating policies and procedures of the Pharmaceutical Management Agency ("PHARMAC"), 2nd edition. Wellington: PHARMAC; January 2001. Available online. URL: http://www.pharmac.govt.nz/pdf/opps.pdf (Section 3.3.3 "PHARMAC will carry out appropriate consultation on the classification of pharmaceuticals into therapeutic sub-groups and its application of reference pricing in respect of a particular sub-group") Accessed August 2005.
12. Pharmacology and Therapeutics Advisory Committee (PTAC). Wellington: PHARMAC. Available online. URL: http://www.pharmac.govt.nz/ptac.asp Accessed August 2005.
13. Frizelle FA. NZMJ response: pharmaceutical industry and medical publishing. N Z Med J. 2005;118(1481). URL: http://www.nzma.org.nz/journal/118-1215/1481/
14. Metcalfe S, Moodie P, McNee W, et al. PHARMAC and tobacco control in New Zealand: two licensed funded options are already available (with responses by Holt et al and the Editor). N Z Med J. 2005;118(1217). URL: http://www.nzma.org.nz/journal/118-1217/1544/
15. Mann S. Dihydropyridines, felodipine, and PHARMAC. N Z Med J. 2005;118(1218). URL: http://www.nzma.org.nz/journal/118-1218/1569/
16. Analysis of HealthPac dispensings claims data and NZHIS hospitalisation data (Metcalfe S. Asthma medicines (SABAs, LABAs and ICSs) and hospitalisations by age and by ethnicity over time. PHARMAC, December 2004) - awaiting publication.